Filing Flows › Pfizer (PFE) › Guidance & outlook
Pfizer (PFE) guidance and outlook
Pfizer (PFE) raised some and lowered other parts of its guidance on Nov 3, 2026: Revenue $62.0B–$64.0B for FY2026; EPS −$2.00 for FY2026; Revenue +2025% for FY2026. Pfizer's 10-Q filed Nov 3, 2026 makes 35 forward-looking statements, 1 of them new and 1 no longer said since the filing before.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $62.0B–$64.0B | raised |
| EPS | FY2026 | −$2.00 | lowered |
| Revenue | FY2026 | +2025% | new |
| Revenue | FY2026 | $1.1B | new |
From the earnings release filed Nov 3, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 3, 2026
- Business section and the Overview of Our Performance, Operating Environment, Strategy and Outlook section within MD&A of our 2025 Form 10-K.
- Realigning Our Cost Base Program ––In the third quarter of 2026, we announced $1.0 billion of additional anticipated net cost savings associated with this program driven by further productivity enhancements from technology and simplification efforts across our commercial, R&D and enabling functions.
- We expect one-time costs to achieve the additional savings to be incurred through 2029 and to total approximately $2.0 billion.
- updated · Manufacturing Optimization Program ––In the third quarter of 2026, we announced the next phase of our multi-year program designed to reduce our cost of goods sold focused on network structure changes, product portfolio enhancements and additional operational efficiencies which is expected to deliver additional anticipated savings of approximately $1.5 billion from 2027 through 2029.
- We anticipate a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years.
- In 2026, we expect an unfavorable revenue impact from patent-based or regulatory exclusivity expiries of approximately $1.1 billion.
- With respect to the U.S., we expect to see continued focus by the U.S. government and states on regulating drug pricing and access to medicine, including but not limited to, international reference pricing, including Most-Favored-Nation (MFN) drug pricing.
- We do not expect a material, incremental impact from the IRA Medicare Part D Redesign in 2026 versus the baseline set in 2025.
- Presidential administration, Congress and states, including, among others, increased, decreased, withdrawn or new regulatory requirements, including changes in requirements for licensure, changes, delays or failure to receive recommendations, reimbursement and regulatory approvals and coverage for our vaccines and medicines, as well as potential impacts on our activities in markets outside of the U.S., could have…
- We do not currently anticipate the availability of raw materials to have a significant impact on our operations in 2026, but are monitoring potential supply chain disruptions as a result of ongoing geopolitical and trade negotiations, which could, among other things, impact costs.
- Global Trade Environment ––Issued or future executive orders or other new or changes in laws, regulations or policies regarding tariffs or other trade or foreign policy, could have a material adverse effect on our business, earnings, cash flow, liquidity and financial guidance.
- We will continue to monitor developments and any potential impacts on our future financial results and business.
Pfizer's latest quarter
Pfizer, Q3 2026: revenue $16.6B (-0.4% year over year), operating margin 20.4%, net earnings $3.3B, operating cash flow $5.4B. The chart follows the revenue to costs, profit and cash.
Questions
Did Pfizer raise or lower its guidance?
Pfizer (PFE) raised some and lowered other parts of its guidance on Nov 3, 2026: Revenue $62.0B–$64.0B for FY2026; EPS −$2.00 for FY2026; Revenue +2025% for FY2026.
What does Pfizer expect?
Manufacturing Optimization Program ––In the third quarter of 2026, we announced the next phase of our multi-year program designed to reduce our cost of goods sold focused on network structure changes, product portfolio enhancements and additional operational efficiencies which is expected to deliver additional anticipated savings of approximately $1.5 billion from 2027 through 2029. potential impact, of tariffs and pricing dynamics on our business and operations; global economic and/or geopolitical instability, foreign exchange rate fluctuations and inflationary pressures; our anticipated cash
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.